-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, June 18, recently, Kelun Pharmaceutical Co.
, Ltd.
reported the production of amino acids (15) peritoneal dialysate and erlotinib hydrochloride tablets under the new registration classification into the administrative examination and approval stage, and erlotinib hydrochloride tablets became the fourth domestic producer
.
Since 2021, 9 products of Kelun Pharmaceutical have been approved for marketing and deemed to have been reviewed
.
, Ltd.
reported the production of amino acids (15) peritoneal dialysate and erlotinib hydrochloride tablets under the new registration classification into the administrative examination and approval stage, and erlotinib hydrochloride tablets became the fourth domestic producer
.
Since 2021, 9 products of Kelun Pharmaceutical have been approved for marketing and deemed to have been reviewed
.
Source: official website of the State Drug Administration
Erlotinib is the first-generation EGFR inhibitor developed by Roche.
It was first approved by the FDA in 2004 and entered the domestic market in 2006
.
Erlotinib reached a global sales peak of 1.
339 billion Swiss francs in 2013.
Since then, sales have gradually declined due to the expiration of the patent
.
It was first approved by the FDA in 2004 and entered the domestic market in 2006
.
Erlotinib reached a global sales peak of 1.
339 billion Swiss francs in 2013.
Since then, sales have gradually declined due to the expiration of the patent
.
In China, the total sales of erlotinib hydrochloride tablets in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and physical pharmacies in cities in China in 2020 will exceed 300 million yuan
.
At present, three domestic companies , Shanghai Chuangnuo Pharmaceutical (Shipiyao Ouyi is the marketing license holder), Hausen Pharmaceuticals, and Suzhou Terui Pharmaceuticals, have been approved for production of erlotinib hydrochloride tablets and are deemed to have been reviewed.
In addition, the products of 6 companies, including Xinlitai, Nanjing Youke Pharmaceutical, and Hunan Kelun Pharmaceutical, are under review.
Among them, Hunan Kelun Pharmaceutical took the lead in entering the administrative examination and approval stage and sprinted to the fourth domestically-made company
.
.
At present, three domestic companies , Shanghai Chuangnuo Pharmaceutical (Shipiyao Ouyi is the marketing license holder), Hausen Pharmaceuticals, and Suzhou Terui Pharmaceuticals, have been approved for production of erlotinib hydrochloride tablets and are deemed to have been reviewed.
In addition, the products of 6 companies, including Xinlitai, Nanjing Youke Pharmaceutical, and Hunan Kelun Pharmaceutical, are under review.
Among them, Hunan Kelun Pharmaceutical took the lead in entering the administrative examination and approval stage and sprinted to the fourth domestically-made company
.
Source: official website of the State Drug Administration
Amino acid (15) peritoneal dialysate is a nutritional supplement product.
The peritoneal dialysis industry is one of the directions of Kelun Pharmaceutical.
At present, the company has peritoneal dialysate (lactate), low-calcium peritoneal dialysate (lactic acid).
Salt-G2.
5%), low-calcium peritoneal dialysate (lactate-G1.
5%) and many other products have been approved for the market
.
The peritoneal dialysis industry is one of the directions of Kelun Pharmaceutical.
At present, the company has peritoneal dialysate (lactate), low-calcium peritoneal dialysate (lactic acid).
Salt-G2.
5%), low-calcium peritoneal dialysate (lactate-G1.
5%) and many other products have been approved for the market
.
Products approved for marketing by Kelun Pharmaceutical since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Meinenet, since 2021, Kelun Pharmaceuticals has already approved 9 products for the market.
These 9 products have been submitted for production under the new registration classification.
After approval, they are deemed to have passed the consistency evaluation
.
These 9 products have been submitted for production under the new registration classification.
After approval, they are deemed to have passed the consistency evaluation
.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.
com database, official website of the State Drug Administration, etc.
Medical Network News, June 18, recently, Kelun Pharmaceutical Co.
, Ltd.
reported the production of amino acids (15) peritoneal dialysate and erlotinib hydrochloride tablets under the new registration classification into the administrative examination and approval stage, and erlotinib hydrochloride tablets became the fourth domestic producer
.
Since 2021, 9 products of Kelun Pharmaceutical have been approved for marketing and deemed to have been reviewed
.
, Ltd.
reported the production of amino acids (15) peritoneal dialysate and erlotinib hydrochloride tablets under the new registration classification into the administrative examination and approval stage, and erlotinib hydrochloride tablets became the fourth domestic producer
.
Since 2021, 9 products of Kelun Pharmaceutical have been approved for marketing and deemed to have been reviewed
.
Source: official website of the State Drug Administration
Erlotinib is the first-generation EGFR inhibitor developed by Roche.
It was first approved by the FDA in 2004 and entered the domestic market in 2006
.
Erlotinib reached a global sales peak of 1.
339 billion Swiss francs in 2013.
Since then, sales have gradually declined due to the expiration of the patent
.
It was first approved by the FDA in 2004 and entered the domestic market in 2006
.
Erlotinib reached a global sales peak of 1.
339 billion Swiss francs in 2013.
Since then, sales have gradually declined due to the expiration of the patent
.
In China, the total sales of erlotinib hydrochloride tablets in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and physical pharmacies in cities in China in 2020 will exceed 300 million yuan
.
At present, three domestic companies , Shanghai Chuangnuo Pharmaceutical (Shipiyao Ouyi is the marketing license holder), Hausen Pharmaceuticals, and Suzhou Terui Pharmaceuticals, have been approved for production of erlotinib hydrochloride tablets and are deemed to have been reviewed.
In addition, the products of 6 companies, including Xinlitai, Nanjing Youke Pharmaceutical, and Hunan Kelun Pharmaceutical, are under review.
Among them, Hunan Kelun Pharmaceutical took the lead in entering the administrative examination and approval stage and sprinted to the fourth domestically-made company
.
.
At present, three domestic companies , Shanghai Chuangnuo Pharmaceutical (Shipiyao Ouyi is the marketing license holder), Hausen Pharmaceuticals, and Suzhou Terui Pharmaceuticals, have been approved for production of erlotinib hydrochloride tablets and are deemed to have been reviewed.
In addition, the products of 6 companies, including Xinlitai, Nanjing Youke Pharmaceutical, and Hunan Kelun Pharmaceutical, are under review.
Among them, Hunan Kelun Pharmaceutical took the lead in entering the administrative examination and approval stage and sprinted to the fourth domestically-made company
.
Source: official website of the State Drug Administration
Amino acid (15) peritoneal dialysate is a nutritional supplement product.
The peritoneal dialysis industry is one of the directions of Kelun Pharmaceutical.
At present, the company has peritoneal dialysate (lactate), low-calcium peritoneal dialysate (lactic acid).
Salt-G2.
5%), low-calcium peritoneal dialysate (lactate-G1.
5%) and many other products have been approved for the market
.
The peritoneal dialysis industry is one of the directions of Kelun Pharmaceutical.
At present, the company has peritoneal dialysate (lactate), low-calcium peritoneal dialysate (lactic acid).
Salt-G2.
5%), low-calcium peritoneal dialysate (lactate-G1.
5%) and many other products have been approved for the market
.
Products approved for marketing by Kelun Pharmaceutical since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Meinenet, since 2021, Kelun Pharmaceuticals has already approved 9 products for the market.
These 9 products have been submitted for production under the new registration classification.
After approval, they are deemed to have passed the consistency evaluation
.
These 9 products have been submitted for production under the new registration classification.
After approval, they are deemed to have passed the consistency evaluation
.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.
com database, official website of the State Drug Administration, etc.
Medical Network News, June 18, recently, Kelun Pharmaceutical Co.
, Ltd.
reported the production of amino acids (15) peritoneal dialysate and erlotinib hydrochloride tablets under the new registration classification into the administrative examination and approval stage, and erlotinib hydrochloride tablets became the fourth domestic producer
.
Since 2021, 9 products of Kelun Pharmaceutical have been approved for marketing and deemed to have been reviewed
.
, Ltd.
reported the production of amino acids (15) peritoneal dialysate and erlotinib hydrochloride tablets under the new registration classification into the administrative examination and approval stage, and erlotinib hydrochloride tablets became the fourth domestic producer
.
Since 2021, 9 products of Kelun Pharmaceutical have been approved for marketing and deemed to have been reviewed
.
Source: official website of the State Drug Administration
Erlotinib is the first-generation EGFR inhibitor developed by Roche.
It was first approved by the FDA in 2004 and entered the domestic market in 2006
.
Erlotinib reached a global sales peak of 1.
339 billion Swiss francs in 2013.
Since then, sales have gradually declined due to the expiration of the patent
.
It was first approved by the FDA in 2004 and entered the domestic market in 2006
.
Erlotinib reached a global sales peak of 1.
339 billion Swiss francs in 2013.
Since then, sales have gradually declined due to the expiration of the patent
.
In China, the total sales of erlotinib hydrochloride tablets in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and physical pharmacies in cities in China in 2020 will exceed 300 million yuan
.
At present, three domestic companies , Shanghai Chuangnuo Pharmaceutical (Shipiyao Ouyi is the marketing license holder), Hausen Pharmaceuticals, and Suzhou Terui Pharmaceuticals, have been approved for production of erlotinib hydrochloride tablets and are deemed to have been reviewed.
In addition, the products of 6 companies, including Xinlitai, Nanjing Youke Pharmaceutical, and Hunan Kelun Pharmaceutical, are under review.
Among them, Hunan Kelun Pharmaceutical took the lead in entering the administrative examination and approval stage and sprinted to the fourth domestically-made company
.
Hospital hospital hospital pharmacy pharmacy pharmacy enterprise enterprise enterprise.
At present, three domestic companies , Shanghai Chuangnuo Pharmaceutical (Shipiyao Ouyi is the marketing license holder), Hausen Pharmaceuticals, and Suzhou Terui Pharmaceuticals, have been approved for production of erlotinib hydrochloride tablets and are deemed to have been reviewed.
In addition, the products of 6 companies, including Xinlitai, Nanjing Youke Pharmaceutical, and Hunan Kelun Pharmaceutical, are under review.
Among them, Hunan Kelun Pharmaceutical took the lead in entering the administrative examination and approval stage and sprinted to the fourth domestically-made company
.
Source: official website of the State Drug Administration
Amino acid (15) peritoneal dialysate is a nutritional supplement product.
The peritoneal dialysis industry is one of the directions of Kelun Pharmaceutical.
At present, the company has peritoneal dialysate (lactate), low-calcium peritoneal dialysate (lactic acid).
Salt-G2.
5%), low-calcium peritoneal dialysate (lactate-G1.
5%) and many other products have been approved for the market
.
The peritoneal dialysis industry is one of the directions of Kelun Pharmaceutical.
At present, the company has peritoneal dialysate (lactate), low-calcium peritoneal dialysate (lactic acid).
Salt-G2.
5%), low-calcium peritoneal dialysate (lactate-G1.
5%) and many other products have been approved for the market
.
Products approved for marketing by Kelun Pharmaceutical since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Meinenet, since 2021, Kelun Pharmaceuticals has already approved 9 products for the market.
These 9 products have been submitted for production under the new registration classification.
After approval, they are deemed to have passed the consistency evaluation
.
These 9 products have been submitted for production under the new registration classification.
After approval, they are deemed to have passed the consistency evaluation
.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.
com database, official website of the State Drug Administration, etc.
